GB1381426A - Method of treating mammals and composition comprising oligosaccha ride sulphuric acid esters and nonionic surface active agents - Google Patents

Method of treating mammals and composition comprising oligosaccha ride sulphuric acid esters and nonionic surface active agents

Info

Publication number
GB1381426A
GB1381426A GB1727573A GB1727573A GB1381426A GB 1381426 A GB1381426 A GB 1381426A GB 1727573 A GB1727573 A GB 1727573A GB 1727573 A GB1727573 A GB 1727573A GB 1381426 A GB1381426 A GB 1381426A
Authority
GB
United Kingdom
Prior art keywords
acid ester
polyoxyethylene
surface active
sulphuric acid
aliphatic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB1727573A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Priority to GB1727573A priority Critical patent/GB1381426A/en
Publication of GB1381426A publication Critical patent/GB1381426A/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

1381426 Pharmaceutical compositions CHUGAI SEIYAKU KK 10 April 1973 17275/73 Heading A5B Pharmaceutical compositions useful in the treatment of arteriosclerosis and having increased absorption of an oligosaccharide sulphuric acid ester through the wall of the digestive tract comprise at least one oligosaccharide sulphuric acid ester having an overage degree of polymerization of from 2 to 20, and at least one nonionic surface active agent in an amount of from 1 to 20% by weight based on the weight of the oligosaccharide sulphuric acid ester. The surface active agent may be a polyoxyethylene C 5-20 alcohol ether, a polyoxyethylene aliphatic acid ester, a sorbitan aliphatic acid ester, a polyoxyethylene sorbitan aliphatic acid ester, a polyoxyethylene sorbital aliphatic acid ester, a polyoxyethylene hydrogenated castor oil derivative, glyceryl monoaliphatic acid ester or a sucrose aliphatic acid ester. The compositions may be administered orally in the form of tablets, pills, granules, powders, capsules or aqueous preparations.
GB1727573A 1973-04-10 1973-04-10 Method of treating mammals and composition comprising oligosaccha ride sulphuric acid esters and nonionic surface active agents Expired GB1381426A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB1727573A GB1381426A (en) 1973-04-10 1973-04-10 Method of treating mammals and composition comprising oligosaccha ride sulphuric acid esters and nonionic surface active agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1727573A GB1381426A (en) 1973-04-10 1973-04-10 Method of treating mammals and composition comprising oligosaccha ride sulphuric acid esters and nonionic surface active agents

Publications (1)

Publication Number Publication Date
GB1381426A true GB1381426A (en) 1975-01-22

Family

ID=10092354

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1727573A Expired GB1381426A (en) 1973-04-10 1973-04-10 Method of treating mammals and composition comprising oligosaccha ride sulphuric acid esters and nonionic surface active agents

Country Status (1)

Country Link
GB (1) GB1381426A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0056379A1 (en) * 1980-07-02 1982-07-28 Commw Scient Ind Res Org Controlled release compositions for administration of therapeutic agents to ruminants.
EP0130550A2 (en) * 1983-06-29 1985-01-09 Intermedicat GmbH Pharmaceutical compositions based on heparin and surfactants having an effect on the mucous membranes of the mouth, the nose and/or the throat
EP0147526A1 (en) * 1983-08-27 1985-07-10 BASF Aktiengesellschaft Method of enhancing the enteric resorption of heparin and a heparin preparation so obtained
EP0230023A2 (en) * 1985-12-24 1987-07-29 Marion Merrell Dow Inc. Pharmaceutical compositions for the enhancement of wound healing
EP0479093A1 (en) * 1990-10-03 1992-04-08 F. Hoffmann-La Roche Ag Oligosaccharide derivatives and their use as medicaments
EP1014996A1 (en) * 1997-08-28 2000-07-05 The University Of Washington Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0056379A1 (en) * 1980-07-02 1982-07-28 Commw Scient Ind Res Org Controlled release compositions for administration of therapeutic agents to ruminants.
EP0056379A4 (en) * 1980-07-02 1983-10-07 Commw Scient Ind Res Org Controlled release compositions for administration of therapeutic agents to ruminants.
EP0130550A2 (en) * 1983-06-29 1985-01-09 Intermedicat GmbH Pharmaceutical compositions based on heparin and surfactants having an effect on the mucous membranes of the mouth, the nose and/or the throat
EP0130550A3 (en) * 1983-06-29 1986-12-30 Intermedicat GmbH Pharmaceutical compositions based on heparin and surfactants having an effect on the mucous membranes of the mouth, the nose and/or the throat
EP0147526A1 (en) * 1983-08-27 1985-07-10 BASF Aktiengesellschaft Method of enhancing the enteric resorption of heparin and a heparin preparation so obtained
US4656161A (en) * 1983-08-27 1987-04-07 Basf Aktiengesellschaft Increasing the enteral absorbability of heparin or heparinoids
EP0230023A2 (en) * 1985-12-24 1987-07-29 Marion Merrell Dow Inc. Pharmaceutical compositions for the enhancement of wound healing
EP0230023A3 (en) * 1985-12-24 1988-11-17 Marion Laboratories Inc Pharmaceutical compositions for the enhancement of wound healing
EP0479093A1 (en) * 1990-10-03 1992-04-08 F. Hoffmann-La Roche Ag Oligosaccharide derivatives and their use as medicaments
US5298616A (en) * 1990-10-03 1994-03-29 Hoffmann-La Roche Inc. Sulfated O-polysaccharide-trehaloses
EP1014996A1 (en) * 1997-08-28 2000-07-05 The University Of Washington Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses
EP1014996A4 (en) * 1997-08-28 2000-10-11 Univ Washington Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses

Similar Documents

Publication Publication Date Title
ES424533A1 (en) Slow release pharmaceutical compositions
US5185159A (en) Pharmaceutical composition based on valproic acid and a process for preparing it
KR890009376A (en) Spray dried ibuprofen
EP0165352A3 (en) Clear micellized solutions of fat soluble essential nutrients
DE3420283A1 (en) NIFEDIPINE DRY PREPARATIONS AND METHOD FOR THE PRODUCTION THEREOF
GR3017411T3 (en) Production process of microspheres.
FR2698788B1 (en) Effervescent pharmaceutical composition containing ibuprofen and process for its preparation.
ES8100883A1 (en) Transdermal medication system for isosorbide dinitrate
IE810036L (en) Sustained release compositions
GB1381426A (en) Method of treating mammals and composition comprising oligosaccha ride sulphuric acid esters and nonionic surface active agents
IE821796L (en) Waterless thixotropic composition
KR940011014A (en) Stabilized Superoxide Dismutase (SOD) Compositions
ZA837412B (en) Compressed products with retarded release of active substance
US3777020A (en) Psoriasis treatment with mycophenolic acid
IE801402L (en) Gastric acid neutralizing agents
Windsor et al. Effect of tetracycline on leucocyte ascorbic acid levels
DE2963545D1 (en) Pharmaceutical composition containing all-e- or 13-z-7,8-dehydro-retinoic acid and process for its preparation
US4975423A (en) Inhibition of tumor development
US4391809A (en) Methods for treating psoriasis
DD249186A1 (en) METHOD OF MANUFACTURING A NEW GLIBENCLAMID MEDICAMENT WITH HIGHER BIODEGRADABILITY
JPS5731614A (en) Lipid improver
DE1543733C3 (en) Aluminum bis-alpha- (p-chlorophenoxy) isobutyrate and brightening agents containing this compound as an active ingredient
JPS57158719A (en) Rectal administration pharmaceutical
JPS5513241A (en) Remedy for glaucoma
DE2643303A1 (en) HYPOGLYKAEMICALLY ACTIVE DRUG

Legal Events

Date Code Title Description
CSNS Application of which complete specification have been accepted and published, but patent is not sealed